PMA device
Juvéderm Voluma XC, Vollure XC, Volbella XC, Volux XC, Skinvive
Allergan · Implant, Dermal, For Aesthetic Use (LMH, Class III) · First FDA decision Mar 16, 2023, newest Aug 11, 2026Aesthetic skin, fat and body contouring
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
13
Naming "Juvéderm Voluma XC"
MAUDE reports
0
Brand "Juvéderm Voluma XC", since 2015
PubMed studies
16
Mentioning "Juvéderm Voluma XC"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Juvéderm Voluma XC, Vollure XC, Volbella XC, Volux XC, Skinvive
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
P110033-S091 · Decided Aug 11, 2026 · 582 days after receipt · Normal 180 Day Track
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Juvéderm Voluma XC", any status and sponsor, newest update first.
- A Study to Evaluate the Safety and Effectiveness of GP0112 for Cheek Augmentation and Correction of Midface Contour DeficienciesPivotal-lookingNot yet recruiting
Galderma R&DNot on our public-company list
NCT07909421 · 326 participants (planned) · Start Nov 2026 · Primary completion Jan 2028
Device: GP0112; Juvéderm Voluma XC · For: Cheek Wrinkles; Midface Contour Deficiencies
Sites: Chengdu, China
12 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Juvéderm Voluma XC", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code LMH
16,542 reports: 1,388 malfunction, 15,105 injury, 12 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Juvéderm Voluma XC"[tiab]. The summary above synthesizes these.
- Current Concepts in Filler Injection.
Moradi A, Watson J · Facial Plast Surg Clin North Am · 2015Review
- Chin reinforcement using the hyaluronic acid injectable filler VYC-20L and VYC-25L.
Mohammed GF, Al-Dhubaibi MS, Bahaj SS · J Cosmet Dermatol · 2024
- Hyaluronic Acid Soft Tissue Filler for the Treatment of The Hypoplastic Chin: An Observational Study.
Beer K, Stonehouse A, Dunn M · Dermatol Surg · 2020Observational Study, Research Support, Non-U.S. Gov't
- Filler frontier: what's new and heading West to the US market.
Palm MD · Semin Cutan Med Surg · 2014Review
- VYC-20L is Safe and Effective for Improving Volume and Aesthetic Appearance of the Nose in Chinese Adults.
Li D, Sun J, Zhang Y, et al. · Clin Cosmet Investig Dermatol · 2022
- Midface and perioral volume restoration: a conversation between the US and Italy.
Gilbert E, Calvisi L · J Drugs Dermatol · 2014
- Novel Use of a Volumizing Hyaluronic Acid Filler for Treatment of Infraorbital Hollows.
Hall MB, Roy S, Buckingham ED · JAMA Facial Plast Surg · 2018Observational Study
- How Much Does Filler Apparatus Influence Ease of Injection (and Hence, Potential Safety)?
Ginter A, Lee T, Woodward J · Ophthalmic Plast Reconstr Surg · 2023
- Effect of Stromal Vascular Fraction on Sustained Volume Retention of Five Different Hyaluronic Acid Fillers.
Koo HT, Zhang S, Jin US · Aesthetic Plast Surg · 2022
- Volumizing Hyaluronic Acid Filler for Midface Volume Deficit: Results After Repeat Treatment.
Baumann L, Narins RS, Beer K, et al. · Dermatol Surg · 2015Multicenter Study, Randomized Controlled Trial
- The Kinetics of Reversible Hyaluronic Acid Filler Injection Treated With Hyaluronidase.
Juhász MLW, Levin MK, Marmur ES · Dermatol Surg · 2017Randomized Controlled Trial
- A Multicenter, Single-Blind Randomized, Controlled Study of a Volumizing Hyaluronic Acid Filler for Midface Volume Deficit: Patient-Reported Outcomes at 2 Years.
Few J, Cox SE, Paradkar-Mitragotri D, et al. · Aesthet Surg J · 2015Multicenter Study, Randomized Controlled Trial
Other devices of this type
Also filed under product code LMH.
- RADIESSE® Injectable ImplantMerz North America, Inc. · PMA 2026
- SculptraQ-Med AB · PMA 2024
- Belotero Balance Dermal FillerMerz North America, Inc. · PMA 2026
- Restylane Injectable GelQ-Med AB · PMA 2022
- Restylane® ContourQ-Med AB · PMA 2026
- Juvederm Voluma XCAllergan · PMA 2025
- Restylane® Lyft with LidocaineQ-Med AB · PMA 2025
- Belotero Balance (+) Lidocaine Dermal FillerMerz North America, Inc. · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.